NTT-DOCOMO/NEC
26.2.2024 09:06:25 CET | Business Wire | Press release
NTT DOCOMO, INC. and NEC Corporation announced today that they plan to establish a joint venture company, OREX SAI, INC. on April 1 to provide OREX Packages solutions for the full-scale global deployment of Open RAN services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240226531069/en/
Overview of OREX SAI (Graphic: Business Wire)
OREX SAI will locally source products and services from members of OREX PARTNERS in each market and perform system verifications to deliver mobile networks tailored to the needs of each overseas telecommunications operator. Leveraging NEC’s established business infrastructure and global network in over 50 countries and territories, the joint venture will accelerate its global expansion of Open RAN business.
In addition, DOCOMO and NEC plan to strengthen cooperation with OREX PARTNERS through OREX SAI to promote the commercialization and realization of true Open RAN that enables the interoperability of equipment and systems from diverse vendors.
The joint venture will procure all necessary Open RAN network equipment and software from OREX PARTNERS, and then conduct system verification for the planning and construction of optimal mobile networks tailored to each telecom operator. Full-stack services will include planning, construction, maintenance and operation under the OREX Packages framework.
DOCOMO established the O-RAN ALLIANCE with leading global telecom operators in February 2018 and launched the world’s first nationwide Open RAN 5G service in Japan in March 2020. Since introducing the OREX® brand in February 2023, DOCOMO has been supporting Open RAN verifications for global telecom operators to help realize more open mobile networks around the world.
NEC, having delivered Open RAN solutions to telecom operators in Japan and other countries, was selected by DOCOMO as a vendor for virtualized radio access networks (vRANs), one of DOCOMO’s 5G commercial services in Japan. With extensive experience in building communication infrastructure around the world, NEC offers strong system-integration (SI) capabilities.
In their collaboration with OREX PARTNERS to realize Open RAN, DOCOMO and NEC recognize the importance of optimizing local product and service delivery. In response, they will now form a joint venture company to establish a global system capable of accelerating the realization of Open RAN.
Hiroshi Kobayashi, President and CEO of OREX SAI, said, “We are excited to bring our true Open RAN solutions to telecom operators worldwide through the joint venture OREX SAI, which combines DOCOMO’s Open RAN implementation expertise, OREX’s innovative solutions and NEC’s global system-integration capabilities. We are committed to driving innovation and connectivity for all, making global telecommunications open, seamless and inclusive.”
Going forward, OREX SAI will work with OREX PARTNERS to provide optimal products and services that accelerate the global adoption of high-quality, cost-effective and energy-efficient Open RAN solutions. In addition, they will enhance cooperation with global partners to foster a vibrant and open ecosystem.
The new company will also explore application of the NTT’s IOWN all-photonic network for transmission, the use of low-power servers equipped with optoelectronic devices, and collaboration with the Cognitive Foundation®.
Joint Venture Overview |
|
Official Name |
OREX SAI, INC. |
Headquarters |
59-16 Nisshin-cho, Kawasaki-ku, Kawasaki City, Kanagawa, Japan 210-0024 |
President and CEO |
Hiroshi Kobayashi |
Business |
|
Total Assets |
JPY 16 billion (including capital reserve) |
Establishment |
April 1, 2024 (tentative) |
Shareholders |
DOCOMO 66% and NEC 34% |
OREX is a trademark of NTT DOCOMO, INC.
For more detailed information, please refer to the full press release available at www.docomo.ne.jp/english/info/media_center/pr/
About NTT DOCOMO
NTT DOCOMO, Japan’s leading mobile operator with over 89 million subscriptions, is one of the world’s foremost contributors to 3G, 4G and 5G mobile network technologies. Beyond core communications services, DOCOMO is challenging new frontiers in collaboration with a growing number of entities ("+d" partners), creating exciting and convenient value-added services that change the way people live and work. Under a medium-term plan toward 2020 and beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate innovative services that will amaze and inspire customers beyond their expectations.
https://www.docomo.ne.jp/english/
About NEC Corporation
NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240226531069/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom